Implementing a National Cancer Clinical Trials System for the 21st Century: A Workshop

When: March 21, 2011 (7:30 AM Eastern)

Topics Biomedical and Health Research, Diseases, Health Care Workforce, Health Services, Coverage, and Access, Quality and Patient Safety
Activity: National Cancer Policy Forum
Board: Board on Health Care Services

Event Description

In April 2010, an IOM consensus report, A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program, was released to the public.  The authoring committee concluded that:

“Collectively, the implementation of [the committee’s] recommendations would reinvigorate the Clinical Trials Cooperative Group Program for the 21st century and strengthen its position as a critical component of the translational pathway from scientific discovery to improved treatment outcomes for patients with cancer. Modifying any particular element of the Program or the clinical trials process will not suffice; changes across the board are urgently needed. All participants and stakeholders, including physicians, patients, and health care insurers, as well as NCI, other federal agencies, academia, foundations, and industry, must reevaluate their current roles and responsibilities in cancer clinical trials and work together to develop a more effective and efficient multidisciplinary trials system.”

Together with the American Society of Clinical Oncology, the National Cancer Policy Forum hosted a workshop to examine efforts to implement the recommendations of the IOM report.  Because of the necessity for diverse stakeholders to work toward a common goal, this workshop (and the second workshop in 2013) convened stakeholders for discussions of how best to achieve the aims underlying the IOM recommendations and to summarize progress thus far.

The goals of the workshops were to:

   1. Establish a venue to promote a collaborative approach by all stakeholders to implement recommended changes;
   2. Provide a forum to ensure public involvement;
   3. Document changes that take place to enable accountability to policymakers; and
   4. Facilitate progress toward the IOM committee’s goal of ensuring the continued viability and increased productivity of an NCI-funded clinical trials system with widespread academic involvement and community outreach.

If you are not able to participate in person, there is an option to attend by conference call. Please email Michael Park for more information at

Planning committee:

Richard L. Schilsky, M.D. (Chair)
Jan C. Buckner, M.D.
Michael A. Caligiuri, M.D.
William S. Dalton, Ph.D., M.D.
James H. Doroshow, M.D., FACP
Roy Herbst, M.D., Ph.D.
John Hohneker, M.D.
John Mendelsohn, M.D.
Sharon B. Murphy, M.D.
George W. Sledge, Jr., M.D.
Mary Lou Smith, J.D., MBA

Upcoming Meetings for this Activity

Previous Meetings for this Activity

Also of Interest